Training group(N = 1199) | Validation group(N = 515) | Overall (N = 1714) | X2 | P | |
---|---|---|---|---|---|
Age, years | 2.442 | 0.486 | |||
< 50 | 49 (4.1%) | 25 (4.9%) | 74 (4.3%) | ||
50–59 | 190 (15.8%) | 73 (14.2%) | 263 (15.3%) | ||
60–69 | 303 (25.3%) | 119 (23.1%) | 422 (24.6%) | ||
> 69 | 657 (54.8%) | 298 (57.9%) | 955 (55.7%) | ||
Sex | 0.057 | 0.811 | |||
Female | 350 (29.2%) | 154 (29.9%) | 504 (29.4%) | ||
Male | 966 (72.1%) | 401 (69.7%) | 1367 (71.4%) | ||
Race | Fisher | 0.268 | |||
American Indian/Alaska Native | 2 (0.2%) | 1 (0.2%) | 3 (0.2%) | ||
Asian or Pacific Islander | 44 (3.7%) | 29 (5.6%) | 73 (4.3%) | ||
Black | 99 (8.3%) | 40 (7.8%) | 139 (8.1%) | ||
White | 1054 (87.9%) | 445 (86.4%) | 1499 (87.5%) | ||
Grade | Fisher | 0.596 | |||
I | 9 (0.8%) | 3 (0.6%) | 12 (0.7%) | ||
II | 42 (3.5%) | 12 (2.3%) | 54 (3.2%) | ||
III | 369 (30.8%) | 155 (30.1%) | 524 (30.6%) | ||
IV | 779 (65.0%) | 345 (67.0%) | 1124 (65.6%) | ||
T | 0.319 | 0.572 | |||
Ta/Tis/T1 | 181 (15.1%) | 84 (16.3%) | 265 (15.5%) | ||
T2/T3/T4 | 1018 (84.9%) | 431 (83.7%) | 1449 (84.5%) | ||
N | Fisher | 0.670 | |||
N0 | 708 (59.0%) | 303 (58.8%) | 1011 (59.0%) | ||
N1 | 209 (17.4%) | 100 (19.4%) | 309 (18.0%) | ||
N2 | 272 (22.7%) | 107 (20.8%) | 379 (22.1%) | ||
N3 | 10 (0.8%) | 5 (1.0%) | 15 (0.9%) | ||
Histologic type (transitional cell cancer) | Fisher | 0.593 | |||
NOS (8120) | 782 (65.2%) | 321 (62.3%) | 1103 (64.4%) | ||
Spindle cells (8122) | 23 (1.9%) | 8 (1.6%) | 31 (1.8%) | ||
Papillary (8130) | 386 (32.2%) | 183 (35.5%) | 569 (33.2%) | ||
Micropapillary (8131) | 8 (0.7%) | 3 (0.6%) | 11 (0.6%) | ||
Tumor size, mm | 1.259 | 0.739 | |||
<30 | 151 (12.6%) | 73 (14.2%) | 224 (13.1%) | ||
30–49 | 354 (29.5%) | 153 (29.7%) | 507 (29.6%) | ||
50–99 | 610 (50.9%) | 258 (50.1%) | 868 (50.6%) | ||
>99 | 84 (7.0%) | 31 (6.0%) | 115 (6.7%) | ||
Surgery | < 0.01 | 1 | |||
No | 55 (4.6%) | 23 (4.5%) | 78 (4.6%) | ||
Yes | 1144 (95.4%) | 492 (95.5%) | 1636 (95.4%) | ||
Chemotherapy | 0.475 | 0.491 | |||
No | 554 (46.2%) | 248 (48.2%) | 802 (46.8%) | ||
Yes | 645 (53.8%) | 267 (51.8%) | 912 (53.2%) | ||
Radiotherapy | 0.153 | 0.696 | |||
No | 931 (77.6%) | 459 (79.8%) | 1516 (79.2%) | ||
Yes | 268 (22.4%) | 110 (21.4%) | 378 (22.1%) |